Amgen to acquire biotech company Teneobio for up to $2.5bn
Teneobio will receive an upfront cash payment of $900m at the closing of the deal that is expected in the coming months.
Drug Development
AbbVie and Calico extend partnership on drugs for age-related diseases
The companies will co-invest nearly $1bn for the alliance, which will extend next year until...
Dyadic and Rubic to develop Covid-19 vaccines for African markets
Rubic will pay a licencing fee that is equal to a proportion of product sales...
Nothing to sneeze at: nasal sprays to tackle Covid-19
Pharmaceutical Technology takes a look at some of the nasal sprays in development for the...
PerkinElmer agrees to acquire antibody maker BioLegend for $5.25bn
On acquisition, BioLegend’s campus in San Diego will be turned into PerkinElmer’s CoE to develop...
FDA approves GSK’s shingles vaccine for immunocompromised adults
The vaccine was first approved in the US in 2017 to prevent the disease in individuals aged 50 years or above.
Adagio and Biocon collaborate to develop antibody therapy for Covid-19
Biocon will obtain data from Adagio’s EUA submissions to pursue approval for the treatment in India and other emerging markets.
Chief.AI launches pay-as-you-go AI platform for drug discovery
The machine learning operations platform has launched the first no-code, pay-as-you-go artificial intelligence platform for drug discovery.
FDA approves AstraZeneca’s Bydureon BCise for paediatric type 2 diabetes
The once-weekly GLP-1 RA therapy is intended to be used as an adjunct to diet and exercise.
Arvinas and Pfizer enter up to $2.4bn deal to develop breast cancer drug
As per the agreement, Pfizer will invest $350m in Arvinas, representing about 7% of the stake.
Innovation’s drug shows antiviral activity against Covid-19 in study
Brilacidin is currently being assessed in a Phase II clinical trial in hospitalised patients with moderate-to-severe Covid-19.
